SUMMARY In 31 hypertensive patients the effect of chronic oral administration of the beta blocking agent propranolol on regional cerebral blood flow (rCBF) was studied, using the non-invasive 133 Xenon inhalation technique. The results of the measurements were compared to the rCBF obtained in an agematched normal control group. Our study shows that during long-term therapy with low doses of proprano lol (< 120 mg/daily) the rCBF is unaffected, but it is increased significantly if higher doses (> 120 mg/daily) are used. In all six patients who served as their own control, as they had basic rCBF measurements before or during low-dose propranolol, the rCBF on high-dose propranolol became significantly increased. The possible mechanisms which may cause the increased rCBF on high-dose propranolol are discussed.
IT HAS BEEN SHOWN that the cerebral vessels are supplied by nprepinephrine-containing nerve fibers 17 and there is also evidence for the presence of alpha and beta adrenergic receptors in the micro-vessels of the brain.
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Alpha adrenergic receptor stimulation or blockage was shown to decrease or increase, respec tively, the cerebral blood flow (CBF), [11] [12] [13] [14] but the effect of the pharmacological manipulation of the beta recep tors on the CBF is not well established. Stimulation of / these receptors with isoproterenol was shown by some authors to have no effect' 5 and by others to increase [16] [17] CBF, while beta blockade, mainly by propranolol, produced either no effect [15] [16] [17] [18] or a decrease [19] [20] [21] [22] [23] in CBF in experimental animals and in humans.
In spite of the wide use of beta blocking agents in the management of patients with hypertension, very little data is available on the effect of these drugs on the human cerebral circulation. If chronic beta blockade is associated with a reduction in the CBF, as it was shown by the above quoted investigators in acute stud ies,! 9-23 this drug could become potentially harmful for hypertensive patients and perhaps may even increase the risk of cerebral ischemia. Therefore, in this study we measured CBF in hypertensive subjects treated chronically with various doses of propranolol and compared the results with the CBF measured in a normotensive untreated age-matched control group.
Patients and Methods
Thirty-one ambulatory patients with essential hyper tension were included in this study. Each patient gave his agreement and consent for participating in the study according to its protocol, after the explanatory details were given. The patients were free from neurological, hepatic, renal, pulmonary or other clinical conditions, as established by meticulous medical history. Physical examination and laboratory tests were within the nor mal limit including PC0 2 and hemoglobin values. Hy pertension was defined if the mean of three separate measurements of the diastolic pressure was 100 mm Hg or higher. At the beginning of the study 27 patients were already on prolonged propranolol treatment and CBF was measured with the below described method, on two different occasions within 1-4 weeks during the therapy. In two of these patients, the dosage was in creased after the first set of CBF measurements and the study was repeated while the patient received the higher dosage. Four other patients had no previous treatment and after basic rCBF measurement, propran olol was started and after one month of treatment, rCBF was repeated. In none of the patients was a significant change in blood pressure observed between the two CBF measurements. No other drug but pro pranolol was given to any of the patients during the study period.
The regional CBF (rCBF) was measured by the 133 Xenon inhalation technique developed and de scribed in detail by Obrist et al 24 -25 and used by us in previous studies. 26 Briefly, the study was conducted in the resting relaxed state, in a darkened room with the patient lying on a bed with plugged ears and closed eyes. After adjustment to the apparatus, 133 Xenon mixed with air (2.5 mCi/1) was inhaled for one minute through a close-fitting face mask and a non-rebreathing system. The clearance of 133 Xenon from the brain was recorded for 10 minutes by 8 pairs of Nal collimated scintillation detectors incorporated into an on-line computerised system and applied externally over ho mologous regions of the skull with the head relating to the probes in a standard position. The concentration of the radioisotope in the expired air, sampled by a thin catheter ending in the face mask and connected to a vacuum pump, was monitored by a separate detector. The end-tidal concentration of the 133 Xenon in the ex pired air made an "air curve" which was used to correct the "head curves" for recirculation of the in haled radioisotope. The rCBF was computed for each "head curve" as the Initial Slope Index (ISI), derived from the initial slope of the clearance curves between the second and third minutes. Blood brain partition coefficient of '"Xenon was arbitrarily chosen as 1 and ISI data are presented in ml/100 g/min units. The ISI values obtained in our patients were compared with those obtained in a series of 101 healthy, non-hospital ized normotensive control subjects aged 38 to 70 years (mean 53.6). The control values were used to obtain the age-matched expected rCBF, i.e., the expected rCBF values for each patient according to age.
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Results
The 31 patients included in this study were divided according to the daily dose of propranolol intake (table  1) . Group 1 included those 20 patients who received 40-100 mg propranolol daily and Group 2 included those 13 patients who received 120-200 mg proprano lol daily. There were 12 males and 8 females, aged 44 to 76 years (mean age 59.1 years) in Group 1 and 6 males and 7 females, aged 39 to 72 years (mean age 59.4 years) in Group 2. The mean arterial blood pres sure at the time of the study in Group 2 was slightly higher than in Group 1, but this difference was statisti cally non-significant (table 2) . No differences were found between the rCBF measured in the patients re ceiving low-dose propranolol (Group 1) and the ex pected age-matched control. However, a significant increase, by 19.6%, in rCBF was found in the group of patients receiving propranolol 120 mg/day or more (Group 2) as compared to the expected age-matched rCBF (table 2). The increase in rCBF during chronic high-dose propranolol therapy was demonstrated also in six of our patients who served as controls of them selves: four of these patients received no therapy at the time of entering the study and two others received 40 mg propranolol daily. All six had rCBF values almost identical to the expected values while on chronic lowdose propranolol and in all patients propranolol 120- -2 patients on low dose propranolol treatment 4 patients with no previous propranolol treatment 160 mg daily was followed by a significant rise in rCBF one month later ( fig. 1 ).
Discussion
Our results show that the chronic administration of high-dose propranolol (more than 120 mg/day) in creases rCBF whereas a relatively lower dose has no such effect. These findings are different from those reported by Griffith et al 27 who found that the rCBF in hypertensive patients remained unaltered not only dur ing administration of low doses of beta blocking agents but also in those who received high doses. Acute ad ministration of these drugs was demonstrated to reduce rCBF in hypertensive patients by Hares et al, 23 an ef fect not observed by either Griffith and associates 27 or by us during chronic propranolol therapy.
The cause for the increase in rCBF during chronic administration of high-dose propranolol is not clear. It is unlikely that this effect is due to the specific block ade of beta adrenergic receptors by propranolol in the cerebral vessels, since in this case one would expect a similar change, possibly to a lesser degree, also in the group who received the low-dose propranolol. There is a possibility that chronic high-dose propranolol en- 29 perhaps chronic high dose propranolol may have a similar di rect vasodilating effect on cerebral blood vessels. Six of our patients had both a control rCBF measurement (without propranolol or on low-dose propranolol) and a second measurement on high-dose propranolol; al though no patient showed a change in systemic blood pressure between the two measurements, the second test demonstrated a higher rCBF. This provides proof for the assumption that a decrease in the cerebrovascu lar resistance due to the high-dose propranolol must have induced the increase in rCBF. The cerebrovascu lar resistance in patients with untreated hypertension is most probably increased, which helps to maintain a normal rCBF in the presence of the increased systemic pressure.
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This high resistance seems to be unaltered by the low-dose propranolol (our Group 1) or by meth yldopa.
26
The clinical significance of a chronically decreased z cerebrovascular resistance in patients on high-dose / propranolol and the consequent permanent increase in flow, is not clear. It has generally been accepted to look upon the initiation of a vigorous hypotensive ther apy as being dangerous to the patient as sudden de crease in blood pressure can be followed by a sudden reduction in rCBF resulting in syncope or even isch emic brain damage; this has usually been described to follow methyldopa therapy, 31 but not the administra tion of propranolol. This is compatible with the results of our study with chronic propranolol treatment which shows a long-term increase in rCBF while receiving this drug, and as mentioned above, this is best ex plained by a local vasodilating effect of this drug on the cerebral circulation. However, there is a possibility that the chronic increase in rCBF during prolonged propranolol treatment may not exclusively be benefi cial, as a hyperfusion of the brain may be followed by congestion of the brain vessels which under certain circumstances can culminate in brain edema and in the clinical condition of hypertensive encephalopathy. 32 Furthermore, an increased rCBF may be a precipitat ing factor for hemorrhage, which is usually considered if a hypertensive patient develops stroke. Whether the incidence of strokes in hypertensive patients is influ enced by long-term therapy with high-dose proprano lol can be determined only by a long-term follow-up of a large number of patients. 
